**Appendix A**

**Figure A1.** Effect of enzalutamide, dexamethasone, or everolimus on taxane-resistant cells. (**A**) Resistance of LN95-P, LN95-C, and LN95-DR cell viability to 10 μM enzalutamide for 72 h; (**B**) Dose response of dexamethasone on the growth and viability of LN95-P cells; ( **C**) Levels of proteins related to the PI3K/Akt/mTOR axis in whole cell lysates; ( **D**) Dose response of everolimus on the viability of LN95-P, LN95-C, and LN95-DR cells.
